Physician profile
Robert B Gwinn
NPI 1831194158
$1,056.60
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $441 · 2022: $49.92 · 2023: $38.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $38.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $38.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $239.05 | 2019-2020 | |
| Novo Nordisk INC | $190.79 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $170.68 | 2019-2020 | |
| Lilly USA, LLC | $127.58 | 2019-2020 | |
| Abbvie INC. | $74.44 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $51.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.04 | 2020 | |
| Pfizer INC. | $29.94 | 2020 | |
| Amarin Pharma, INC. | $28.66 | 2020 | |
| Amgen INC. | $26.65 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.27 | 2019 | |
| Philips North America LLC | $15.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.78 | 2019 | |
| Grifols USA, LLC | $12.24 | 2019 | |
| Mylan Specialty L.P. | $12.14 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gwinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.